89848-51-1

Basic information

• Product Name: Butyl Itraconazole
• Synonyms: Butyl Itraconazole;cis-2-Butyl-4-[4-[4-[4-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylMethyl)-1,3-dioxolan-4-yl]Methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;Itraconazole EP IMpurity F;Itraconazole iMpurity F;4-(4-(4-(4-(((2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-butyl-1H-1,2,4-triazol-5(4H)-one;Itraconazole Butyl Analog
• CAS NO: 89848-51-1
• Molecular Formula: C₃₅H₃₈Cl₂N₈O₄
• Molecular Weight: 705.63342
• Product Categories: Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 89848-51-1.mol

Chemical Properties

• Boiling Point: 854.2±75.0 °C(Predicted)
• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• PKA: 6.38±0.40(Predicted)
• CAS DataBase Reference: Butyl Itraconazole(CAS DataBase Reference)
• NIST Chemistry Reference: Butyl Itraconazole(89848-51-1)
• EPA Substance Registry System: Butyl Itraconazole(89848-51-1)

Safety Data

• Hazardous Substances Data: 89848-51-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Butyl Itraconazole is used as an antimycotic agent for the treatment of various fungal infections. Its novel structure may offer improved efficacy and reduced side effects compared to traditional antifungal medications.
Used in COVID-19 Research:
As a COVID-19 related research product, Butyl Itraconazole is being investigated for its potential antiviral properties against the SARS-CoV-2 virus. Its unique structure may provide new insights into the development of effective treatments for COVID-19.
Used in Drug Delivery Systems:
Butyl Itraconazole may also be utilized in the development of advanced drug delivery systems, enhancing its bioavailability and targeting specific cells or tissues. This could improve the overall effectiveness of the compound in treating fungal infections and potentially other diseases, including COVID-19.

Upstream product

• 89848-20-4 1-butyl-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one 
• 67914-86-7 cis-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl methanesulfonate 
• 38212-30-5 4-(4-methoxyphenyl)piperazine 
• 100-00-5 4-chlorobenzonitrile 
• 74852-62-3 4-[4-(4-methoxy-phenyl)-piperazin-1-yl]-phenylamine 
• 74852-61-2 1-(4-methoxyphenyl)-4-(4-nitrophenyl)-piperazine 
• 74853-07-9 2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl ]-phenyl]-3H-1,2,4-triazol-3-one 
• 74852-89-4 N-{4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl}hydrazinecarboxamide 
• 89848-15-7 1-butyl-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one 
• 74853-06-8 phenyl (4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)carbamate 

Relevant articles and documents

Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones

A series of novel triazol-3-ones has been synthesized, and their in vitro and in vivo antifungal properties are reported. Traconazole. which displays a pronounced oral activity against vaginal candidosis in rats and against microsporosis in guinea pigs, has been selected for clinical evaluation.